Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Tyra Biosciences is set to release its Q2 2025 earnings results on August 6th, with analysts predicting earnings of ($0.53) per share.
• Recent reports indicate that multiple analysts have given the company an average buy rating and set a target price of $30.83 for its shares.
• In a significant insider transaction, Director Gilla Kaplan sold 30,000 shares at an average price of $10.31, reducing her position by 33.47%.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Down 5.1%

TYRA stock traded down $0.56 during trading on Friday, hitting $10.37. 283,932 shares of the company's stock traded hands, compared to its average volume of 226,927. The firm has a market capitalization of $550.54 million, a P/E ratio of -6.36 and a beta of 1.08. The business has a fifty day simple moving average of $10.10 and a two-hundred day simple moving average of $10.79. Tyra Biosciences has a 1 year low of $6.42 and a 1 year high of $29.60.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Gilla Kaplan sold 30,000 shares of the firm's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $10.31, for a total transaction of $309,300.00. Following the transaction, the director directly owned 59,623 shares of the company's stock, valued at approximately $614,713.13. This trade represents a 33.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 61,392 shares of company stock worth $628,358. Company insiders own 15.20% of the company's stock.

Hedge Funds Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Tyra Biosciences in the first quarter valued at approximately $324,000. Goldman Sachs Group Inc. raised its holdings in shares of Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock worth $725,000 after purchasing an additional 13,896 shares during the period. Woodline Partners LP bought a new position in shares of Tyra Biosciences during the first quarter worth about $931,000. Finally, Millennium Management LLC grew its position in Tyra Biosciences by 28.2% in the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company's stock valued at $3,759,000 after buying an additional 89,024 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TYRA shares. Piper Sandler started coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, July 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.